CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.
Times cited: 180
Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCl2A1 as critical target genes.
Journal of Clinical Investigation.
Times cited: 98